Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.

Nakahata S, Syahrul C, Nakatake A, Sakamoto K, Yoshihama M, Nishikata I, Ukai Y, Matsuura T, Kameda T, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Ito A, Takemoto S, Nakano N, Saito M, Iwanaga M, Sagara Y, Mochida K, Amano M, Maeda K, Sueoka E, Okayama A, Utsunomiya A, Shimoda K, Watanabe T, Morishita K.

Haematologica. 2020 Feb 13. pii: haematol.2019.234096. doi: 10.3324/haematol.2019.234096. [Epub ahead of print]

2.

Clinical impact of the CONUT score in patients with multiple myeloma.

Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S.

Ann Hematol. 2020 Jan;99(1):113-119. doi: 10.1007/s00277-019-03844-2. Epub 2019 Nov 25.

PMID:
31768678
3.

Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan.

Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M, Kishiba M, Fujimura Y, Kimura M, Murata K, Nakashima N, Nakayama M, Ohe K, Orii T, Sueoka E, Suzuki T, Yokoi H, Takahashi F, Uyama Y.

Pharmacoepidemiol Drug Saf. 2019 Oct;28(10):1395-1404. doi: 10.1002/pds.4879. Epub 2019 Aug 29.

4.

The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies.

Yamada K, Itoh M, Fujimura Y, Kimura M, Murata K, Nakashima N, Nakayama M, Ohe K, Orii T, Sueoka E, Suzuki T, Yokoi H, Ishiguro C, Uyama Y; MID-NET® project group.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):601-608. doi: 10.1002/pds.4777. Epub 2019 Apr 3.

PMID:
30945387
5.

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations.

Kamachi K, Kubota Y, Nagaie T, Yamaguchi K, Ogusu S, Kidoguchi K, Kusaba K, Kizuka-Sano H, Nishioka A, Yoshimura M, Yokoo M, Ando T, Kai K, Kojima K, Ohshima K, Sueoka E, Kimura S.

Intern Med. 2019 Jul 15;58(14):2073-2077. doi: 10.2169/internalmedicine.2532-18. Epub 2019 Mar 28.

6.

Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine.

Sueoka E, Watanabe T, Mashima T, Shirakami Y, Komori A, Matsuo K, Yoshikawa HY, Cho KA, Park TJ, Seimiya H, Kim EG, Suganuma M, Chung J.

J Cancer Res Clin Oncol. 2019 May;145(5):1263-1271. doi: 10.1007/s00432-019-02887-2. Epub 2019 Mar 11.

PMID:
30859317
7.

Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host Disease.

Sato E, Togawa A, Masaki M, Shirahashi A, Kumagawa M, Kawano Y, Ishikura H, Yamashiro Y, Takagi S, To H, Kobata K, Takeshita M, Kusaba K, Sueoka E, Tamura K, Takamatsu Y, Takata T.

Intern Med. 2019 Mar 15;58(6):877-882. doi: 10.2169/internalmedicine.1706-18. Epub 2018 Nov 19.

8.

The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2339-2349. doi: 10.1007/s00432-018-2765-7. Epub 2018 Oct 20. Review.

9.

Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.

Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S.

Ann Hematol. 2019 Feb;98(2):465-471. doi: 10.1007/s00277-018-3502-7. Epub 2018 Sep 27.

PMID:
30264165
10.

Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy.

Sato A, Nakashima C, Abe T, Kato J, Hirai M, Nakamura T, Komiya K, Kimura S, Sueoka E, Sueoka-Aragane N.

Oncotarget. 2018 Aug 7;9(61):31904-31914. doi: 10.18632/oncotarget.25881. eCollection 2018 Aug 7.

11.
12.

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A, Masunari T, Aoki S, Takizawa J, Suzumiya J, Kimura S.

Int J Hematol. 2018 Oct;108(4):416-422. doi: 10.1007/s12185-018-2506-3. Epub 2018 Jul 24.

PMID:
30043333
13.

Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia.

Kubota Y, Kamachi K, Wakayama K, Kitamura H, Yoshihara M, Hisatomi T, Fukushima N, Ichinohe T, Sueoka E, Kimura S.

Ann Hematol. 2019 Jan;98(1):221-222. doi: 10.1007/s00277-018-3408-4. Epub 2018 Jun 27. No abstract available.

PMID:
29951913
14.

Automated DNA extraction using cellulose magnetic beads can improve EGFR point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments.

Nakashima C, Sato A, Abe T, Kato J, Hirai M, Nakamura T, Komiya K, Sueoka E, Kimura S, Sueoka-Aragane N.

Oncotarget. 2018 May 18;9(38):25181-25192. doi: 10.18632/oncotarget.25388. eCollection 2018 May 18.

15.

Synchronous mantle cell lymphoma and lung adenocarcinoma presenting in a pleural effusion: A rare tumour combination and a potential pitfall of cytodiagnosis.

Kai K, Ryu Y, Kamochi K, Nishioka A, Kubota Y, Nakamura M, Kimura S, Sueoka E, Aishima S.

Cytopathology. 2018 Aug;29(4):400-402. doi: 10.1111/cyt.12532. Epub 2018 Mar 25. No abstract available.

PMID:
29575128
16.

Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions.

Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, Nishiyama M, Hiyama E, Hirohashi N, Sueoka E, Poellinger L, Tanimoto K.

PLoS One. 2018 Feb 21;13(2):e0192136. doi: 10.1371/journal.pone.0192136. eCollection 2018.

17.

Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells.

Fujiki H, Watanabe T, Sueoka E, Rawangkan A, Suganuma M.

Mol Cells. 2018 Feb 28;41(2):73-82. doi: 10.14348/molcells.2018.2227. Epub 2018 Jan 31. Review.

18.

Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia.

Shindo T, Kitaura K, Ureshino H, Kamachi K, Miyahara M, Doi K, Watanabe T, Sueoka E, Shin-I T, Suzuki R, Kimura S.

Oncoimmunology. 2017 Dec 11;7(3):e1405204. doi: 10.1080/2162402X.2017.1405204. eCollection 2018.

19.

Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate.

Fujiki H, Sueoka E, Rawangkan A, Suganuma M.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2401-2412. doi: 10.1007/s00432-017-2515-2. Epub 2017 Sep 23. Review.

20.

Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.

Kobayashi-Watanabe N, Sato A, Watanabe T, Abe T, Nakashima C, Sueoka E, Kimura S, Sueoka-Aragane N.

Lung Cancer. 2017 Aug;110:35-41. doi: 10.1016/j.lungcan.2017.05.017. Epub 2017 May 25.

PMID:
28676216
21.

Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge.

Nakamura T, Watanabe N, Sato A, Komiya K, Umeguchi H, Hosomi T, Hirai M, Sueoka E, Kimura S, Sueoka-Aragane N.

Oncol Lett. 2017 Jun;13(6):4939-4946. doi: 10.3892/ol.2017.6085. Epub 2017 Apr 24.

22.

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.

Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, Hino R, Hanada S, Jo T, Tsukasaki K, Moriuchi Y, Sueoka E, Yoshida S, Suzushima H, Miyahara M, Yamashita K, Eto T, Suzumiya J, Tamura K.

Blood. 2017 Jul 6;130(1):39-47. doi: 10.1182/blood-2017-01-757542. Epub 2017 May 17.

PMID:
28515095
23.

[Japanese Biobanks: Current Status, Problems, and Future Challenges].

Sueoka E.

Rinsho Byori. 2017 Feb;65(2):190-198. Japanese.

PMID:
30762986
24.

Erratum to "Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer" [Lung Cancer 69/2 (2010) 232-238].

Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M, Sato T, Hayashi S, Izumi H, Tsuneoka M, Sueoka E.

Lung Cancer. 2016 Nov;101:148. doi: 10.1016/j.lungcan.2016.05.005. Epub 2016 May 27. No abstract available.

PMID:
27241680
25.

Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.

Ide M, Koba S, Sueoka-Aragane N, Sato A, Nagano Y, Inoue T, Misago N, Narisawa Y, Kimura S, Sueoka E.

Pathol Oncol Res. 2017 Jan;23(1):181-188. doi: 10.1007/s12253-016-0121-2. Epub 2016 Oct 21.

PMID:
27766572
26.

[Clinical Hematology for Specialists of Clinical Laboratory Medicine].

Sueoka E.

Rinsho Byori. 2016 Aug;64(8):965-971. Review. Japanese.

PMID:
30609340
27.

Reversible Liver Steatosis Induced by Chemotherapy of Mixed-phenotype Acute Leukemia.

Nishioka A, Kubota Y, Sueoka E, Kimura S.

Intern Med. 2016;55(8):1025-6. doi: 10.2169/internalmedicine.55.5685. Epub 2016 Apr 15. No abstract available.

28.

[Results of Training for Personnel Involved in Blood-Transfusion Testing Outside of Regular Work Hours at Saga University Hospital].

Yamada M, Yamada N, Higashitani T, Ohta S, Sueoka E.

Rinsho Byori. 2015 Nov;63(11):1259-63. Japanese.

PMID:
26995870
29.

Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus.

Kubota Y, Ichinohe T, Yoshimura M, Itamura H, Hisatomi T, Fukushima N, Sueoka E, Kimura S.

Ann Hematol. 2016 Mar;95(4):653-5. doi: 10.1007/s00277-016-2595-0. Epub 2016 Jan 11. No abstract available.

PMID:
26754632
30.

Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.

Watanabe T, Sato A, Kobayashi-Watanabe N, Sueoka-Aragane N, Kimura S, Sueoka E.

Anticancer Res. 2016 Jan;36(1):95-102.

PMID:
26722032
31.

2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.

Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S.

PLoS One. 2015 Nov 4;10(11):e0141946. doi: 10.1371/journal.pone.0141946. eCollection 2015.

32.

Treatment and survival among 1594 patients with ATL.

Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, Shimokawa M, Kawai K, Suzumiya J, Tamura K; ATL-Prognostic Index Project.

Blood. 2015 Dec 10;126(24):2570-7. doi: 10.1182/blood-2015-03-632489. Epub 2015 Sep 11.

PMID:
26361794
33.

Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Prev. 2015 Mar;20(1):1-4. doi: 10.15430/JCP.2015.20.1.1. Review.

34.

Highlights of the Twelfth Japan-Korea Joint Symposium on Cancer and Ageing Research.

Suganuma M, Park TJ, Sueoka E, Iida K, Tanaka Y.

J Cancer Res Clin Oncol. 2015 Nov;141(11):1953-61. doi: 10.1007/s00432-015-1959-5. Epub 2015 Mar 29.

PMID:
25820597
35.

Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.

Fujiki H, Sueoka E, Watanabe T, Suganuma M.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1511-22. doi: 10.1007/s00432-014-1899-5. Epub 2014 Dec 28. Review.

PMID:
25544670
36.

Correlation between plasma DNA and tumor status in an animal model.

Sueoka-Aragane N, Sato A, Kobayashi N, Ide M, Yokoo M, Nagano Y, Sueoka E, Okada S, Kimura S.

PLoS One. 2014 Dec 2;9(12):e111881. doi: 10.1371/journal.pone.0111881. eCollection 2014.

37.

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A, Takeda Y, Hayashi S, Sueoka E, Kimura S.

Oncol Rep. 2015 Jan;33(1):391-6. doi: 10.3892/or.2014.3560. Epub 2014 Oct 22.

PMID:
25338771
38.

ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.

Yoshimura M, Kojima K, Tomimasu R, Fukushima N, Hayashi S, Sueoka E, Kimura S.

Int J Hematol. 2014 Dec;100(6):611-4. doi: 10.1007/s12185-014-1666-z. Epub 2014 Sep 12.

PMID:
25212679
39.

Therapeutic management in cardiac lymphoma.

Yoshihara M, Itamura H, Fukushima N, Itoh M, Furukawa K, Nagatomo D, Kamachi K, Kitamura H, Shindo T, Kubota Y, Sueoka E, Morita S, Ichinohe T, Kimura S.

Leuk Lymphoma. 2014 May;55(5):1215-7. doi: 10.3109/10428194.2013.828355. Epub 2013 Sep 3. No abstract available.

PMID:
23885797
40.

[Direct identification method for bacteria in positive blood culture bottles using MALDI biotyper].

Uki N, Oho M, Nagasawa Z, Higashitani T, Ohta S, Sueoka E, Miyamoto H.

Rinsho Byori. 2013 Mar;61(3):224-30. Japanese.

PMID:
23785791
41.

Tumor promoters: from chemicals to inflammatory proteins.

Fujiki H, Sueoka E, Suganuma M.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1603-14. doi: 10.1007/s00432-013-1455-8. Epub 2013 Jun 12. Review.

PMID:
23756937
42.

Development of lymphoproliferative diseases by hypoxia inducible factor-1alpha is associated with prolonged lymphocyte survival.

Sueoka E, Sueoka-Aragane N, Sato A, Ide M, Nakamura H, Sotomaru Y, Taya C, Yonekawa H, Kitagawa T, Kubota Y, Kimura S, Nakachi K, Tanimoto K.

PLoS One. 2013 Apr 12;8(4):e57833. doi: 10.1371/journal.pone.0057833. Print 2013.

43.

Platelets with a W127X mutation in GPIX express sufficient residual amounts of GPIbα to support adhesion to von Willebrand factor and collagen.

Takata Y, Kanaji T, Moroi M, Seki R, Sano M, Nakazato S, Sueoka E, Imamura Y, Okamura T.

Int J Hematol. 2012 Dec;96(6):733-42. doi: 10.1007/s12185-012-1216-5. Epub 2012 Nov 11.

PMID:
23143686
44.

Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.

Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S.

J Thorac Oncol. 2012 Sep;7(9):1369-81. doi: 10.1097/JTO.0b013e31825f2821.

45.

Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.

Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Suzumiya J, Tamura K.

J Clin Oncol. 2012 May 10;30(14):1635-40. doi: 10.1200/JCO.2011.38.2101. Epub 2012 Apr 2.

PMID:
22473153
46.

Successful reduced-intensity umbilical cord blood transplant for fulminant hemophagocytic syndrome in an adult with pre-existing rheumatoid arthritis and autoimmune hemolytic anemia.

Itamura H, Fukushima N, Kondo S, Urata C, Tanaka-Yoshimura M, Yokoo M, Ide M, Hisatomi T, Kubota Y, Sueoka E, Ichinohe T, Kimura S.

Leuk Lymphoma. 2012 Nov;53(11):2307-9. doi: 10.3109/10428194.2012.680453. Epub 2012 Apr 19. No abstract available.

PMID:
22452588
47.

[Influences of %T>MIC achievement probability due to the difference of the MIC measurement concentration range-analysis of meropenem for Pseudomonas aeruginosa-].

Nagasawa Z, Nakashima Y, Fukutomi Y, Uki N, Kusaba K, Nagumo F, Ohta S, Sueoka E, Miyamoto H.

Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 2011;22(1-2):11-22. Japanese.

PMID:
22352705
48.

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

PMID:
21990393
49.

A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.

Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S.

J Thorac Oncol. 2011 Oct;6(10):1639-48. doi: 10.1097/JTO.0b013e31822956e8.

50.

Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

Urata C, Yoshimura M, Itamura H, Hisatomi T, Kubota Y, Fukushima N, Sueoka E, Kimura S.

Int J Hematol. 2011 Aug;94(2):216-217. doi: 10.1007/s12185-011-0903-y. Epub 2011 Aug 3. No abstract available.

PMID:
21811773

Supplemental Content

Loading ...
Support Center